Morgan Stanley Sees Policy Risks Receding for Regeneron (REGN) [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
On December 12, Morgan Stanley analyst Terence Flynn raised the firm's price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $768 from $767 and kept an Equal Weight rating. The firm expects many of the policy concerns that weighed on biopharma this year to fade in 2026. As those pressures ease, attention is likely to shift back to company fundamentals, the analyst said in a 2026 outlook note. In other news, on December 23, the Ministry of Health, Labour and Welfare in Japan granted marketing and manufacturing authorization for Dupixent (dupilumab). The approval covers the treatment of bronchial asthma in children ages 6 to 11 with severe or refractory disease whose symptoms are not adequately controlled with existing therapies. This decision expands the earlier approval in Japan, which applied to patients 12 and older. Dupilumab is being jointly developed by Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) under a global collaboration agreement. To date, the dr
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Revamping best-selling drugs to combat patent cliff has limits [Yahoo! Finance]Yahoo! Finance
- Vyriad Secures Final $25M Series B Tranche to Advance In Vivo CAR T Candidate into Clinic [Yahoo! Finance]Yahoo! Finance
- Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial AsthmaGlobeNewswire
- Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 10/28/25 - Beat
REGN
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- REGN's page on the SEC website